Clinical trial
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain
NCT05265052 is registered in ClinicalTrials.gov with 3D Medicines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain
- Lead sponsor
- 3D Medicines
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2026
- Enrollment
- 177 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.